

Special Issue

Selected Papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023)

Message from the Guest Editors

This Special Issue comprises selected papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023), hosted online from 1 to 15 December 2023, an online platform for hosting scholarly e-conferences and discussion groups (<https://iecv2023.sciforum.net/>).

- Vaccines to counter anti-microbial resistance;
- Vaccines to eradicate endemic disease—opportunities and challenges;
- Vaccines to prevent zoonotic transmission—targeting the animal reservoir;
- Vaccine platforms—advantages and disadvantages;
- Clinical trial design for reactive and preventive vaccination;
- Vaccine deployment in outbreak settings—lessons learned;
- Advances in vaccine formulation and adjuvantisation;
- Clinical view on routinisation of RNA vaccines;
- Immune response after vaccination against SARS-CoV-2 in patients with chronic diseases;
- T-cell responses in SARS-CoV-2;
- Novel technology and vaccines development for COVID-19;
- T-cell immunity and HIV-1 pathogenicity;
- Vaccine hesitancy;

Guest Editors

Dr. François Meurens

Swine and Poultry Infectious Diseases Research Center (CRIPA),
Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe,
QC J2S 2M2, Canada

Dr. Fanny Renois

BIOEPAR, INRAE, Oniris, 44307 Nantes, France

Deadline for manuscript submissions



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/178441

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).